This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $90.76 in the latest trading session, marking a +1.43% move from the prior day.
Abbott (ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $90.39, marking a +0.33% move from the previous day.
Why Is Abbott (ABT) Down 6.4% Since Last Earnings Report?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Healthcare Tech & Robotics ETFs in Focus amid COVID-19 Crisis
by Neena Mishra
The pandemic will forever transform our lives; here are some areas that may benefit.
BJ's Wholesale Club, Polaris Industries, Abbott Laboratories, Eldorado Resorts and Apple highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
BJ's Wholesale Club, Polaris Industries, Abbott Laboratories, Eldorado Resorts and Apple highlighted as Zacks Bull and Bear of the Day
3 Medical Product Stocks Set to Beat This Earnings Season
by Trina Mukherjee
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on several factors.
Biotech ETFs Poised to Benefit From Coronavirus
by Neena Mishra
Rising investor interest in coronavirus related stocks will benefit these ETFs
HRC vs. ABT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HRC vs. ABT: Which Stock Is the Better Value Option?
3 Stocks Set to Pop Once the Economy Gets Back to Business
by Tirthankar Chakraborty
We have highlighted three stocks will flourish when the economy reopens. Notably, an increasing number of states are expected to reopen their economies in the first two weeks of May.
The Zacks Analyst Blog Highlights: Cisco, Abbott Laboratories, NextEra Energy, Gilead Sciences and Edwards Lifesciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cisco, Abbott Laboratories, NextEra Energy, Gilead Sciences and Edwards Lifesciences
Top Stock Research Reports for Cisco, Abbott, NextEra & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Cisco (CSCO), Abbott Laboratories (ABT) and NextEra Energy (NEE).
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Coronavirus Makes Biotech ETFs Red Hot
by Sweta Killa
The biotech space of the broader healthcare sector is currently the hottest of all segments buoyed by the COVID-19 pandemic.
4 Top Sectors of Last Week & Their Winning ETFs
by Sanghamitra Saha
These sectors topped last week and beat the broader market in a sweeping move.
Abbott Launches Antibody Test to Detect Coronavirus Infection
by Zacks Equity Research
Abbott (ABT) launches a lab-based serology blood test to detect the presence of antibodies post the coronavirus infection.
5 Best Leveraged ETF Areas of Last Week
by Sanghamitra Saha
If investors can identify the trending investing area amid all the coronavirus chaos, they can easily take a leveraged position on that and beat the broader market.
Stock Market News for Apr 17, 2020
by Zacks Equity Research
Benchmarks closed in the positive territory on Thursday led by gains in tech-related companies.
3 MedTech Stocks Likely to Have Braved Coronavirus Blow in Q1
by Sriparna Ghosal
Despite the widespread coronavirus crisis, there are a few MedTech companies which are expected to have gained in the first quarter.
Optimism Back in Wall Street? ETFs Areas to Win the Most
by Sanghamitra Saha
Wall Street is likely to stage a relief rally on hopes of reopening of American businesses, improving virus outlook and chances of treatment coming on stream.
Healthcare ETFs to Gain on Progress in COVID-19 Antibody Tests
by Sweta Jaiswal, FRM
Along with molecular testing, antibody testing is gaining immense prominence as economies are struggling to reopen.
How To Navigate The Choppy Markets
by Daniel Laboe
22 million filed for unemployment in the past month, the SBA fund ran dry, pandemic case count tops 2 million, and it will likely be months before the economy is able to safely open up. So, is the S&P 500's 28% recovery justified?
5.25M More Jobless Claims, Plus Starts & Permits, Philly Fed Down
by Mark Vickery
Initial and Continuing Jobless Claims, Housing Starts and Building Permits, and the Philly Fed join the latest batch of Q1 earnings reports this morning.
Abbott (ABT) Beats on Q1 Earnings, Suspends '20 Guidance
by Zacks Equity Research
Uncertainties about the duration and impact of the coronavirus pandemic on its overall business compel Abbott (ABT) to suspend its full-year guidance.
Economic Data Deluge
by Zacks Equity Research
Economic Data Deluge
Abbott (ABT) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 18.18% and 8.38%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?